Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Status:
Not yet recruiting
Trial end date:
2024-10-21
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and
dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a
monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin.
Belantamab is a form of targeted therapy because it attaches to specific molecules on the
surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them.
Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response
and are used with other drugs in the treatment of some types of cancer. Giving belantamab
mafodotin, pomalidomide, and dexamethasone may kill more cancer cells.